Kyora

We've developed thin-film implant technologies and advanced manufacturing materials that enable in-body neural interface devices with unprecedented resolution and longevity.

Unlike short-term or low-density systems, this platform enables longitudinal human brain data collection, opening an untapped frontier in neuroscience, neuromodulation, and AI training.

We've developed technology that allows us to perform directed evolution in animal models to generate novel peptides with therapeutic activity grounded on in vivo data, at an unrivaled scale.

By tightly coupling this biological data with AI, we are building a system that can dramatically accelerate peptide engineering, moving from simulation toward AI-biological feedback loops.

We are starting a bio-engineering company founded around an extremely practical product that was engineered using AI. This product could not exist without the ability to engineer peptides through AI-driven methods.

Using early revenue, we plan to tap directly into a growing pipeline of bioengineering PhDs and technical talent from the Knight Campus, capturing creativity for continued product innovation. The goal is a company where AI, biology, and manufacturing are integrated end-to-end.

We are in the process of bringing online clean room in a 1 million sq ft total facility, providing near-term access to scalable, advanced manufacturing infrastructure.

Cleanroom availability at this scale is increasingly scarce nationwide, and this capability materially accelerates both R&D and commercialization timelines.